These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 26673466)

  • 1. Biopharmaceutical Innovation System in China: System Evolution and Policy Transitions (Pre-1990s-2010s).
    Hu H; Chung CC
    Int J Health Policy Manag; 2015 Sep; 4(12):823-9. PubMed ID: 26673466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of government subsidies on innovation of Chinese biopharmaceutical firms: Based on kink threshold model.
    Li Q; Di J; Liu Q
    Front Public Health; 2023; 11():1087830. PubMed ID: 36908409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seizing the strategic opportunities of emerging technologies by building up innovation system: monoclonal antibody development in China.
    Zhang MY; Li J; Hu H; Wang YT
    Health Res Policy Syst; 2015 Nov; 13():64. PubMed ID: 26537659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. With the help of a foreign ally: biopharmaceutical innovation in India after TRIPS.
    Angeli F
    Health Policy Plan; 2014 May; 29(3):280-91. PubMed ID: 23558959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of industry-university-research projects on biopharmaceutical companies' innovation performance: moderating roles of government subsidies for innovation.
    Xia Y; Jia Y
    Front Public Health; 2023; 11():1271364. PubMed ID: 38035308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biopharmaceuticals in China.
    Hu X; Ma Q; Zhang S
    Biotechnol J; 2006 Nov; 1(11):1215-24. PubMed ID: 17089435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current situation and future development of the biopharmaceutical industry in China: A mixed-method study.
    Yang R; Kabba JA; Yao X; Yang C; Chang J; Ji W; Jiang M; Zhao M; Wen J; Fang Y
    Front Pharmacol; 2022; 13():911165. PubMed ID: 36071832
    [No Abstract]   [Full Text] [Related]  

  • 8. Recombinant drug development, regulation, and commercialization: an Indian industry perspective.
    Sahoo N; Manchikanti P
    BioDrugs; 2011 Apr; 25(2):105-13. PubMed ID: 21230010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The biopharmaceutical industry in China: history and future perspectives.
    Gao K; Wang J
    Front Med; 2012 Jun; 6(2):101-11. PubMed ID: 22544299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Priorities and funding. "Knowledge innovation" and the Chinese Academy of Sciences.
    Suttmeier RP; Cao C; Simon DF
    Science; 2006 Apr; 312(5770):58-9. PubMed ID: 16601178
    [No Abstract]   [Full Text] [Related]  

  • 11. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biopharmaceutical innovation and industrial developments in South Korea, Singapore and Taiwan.
    Hsieh CR; Löfgren H
    Aust Health Rev; 2009 May; 33(2):245-57. PubMed ID: 19563313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biotechnology in South Africa.
    Cloete TE; Nel LH; Theron J
    Trends Biotechnol; 2006 Dec; 24(12):557-62. PubMed ID: 17070947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enabling Europe to innovate.
    Dearing A
    Science; 2007 Jan; 315(5810):344-7. PubMed ID: 17234939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation and analysis of leading position in hydrogen fuel cell vehicle innovation network and the influential factors: a case of patent citations in China.
    Yu P; Cai Z; Jiang F; Sun Y
    Environ Sci Pollut Res Int; 2023 Apr; 30(18):53339-53354. PubMed ID: 36856993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of Chinese drug discovery research: impact of hit and lead identification.
    Zhou C; Zhou Y; Wang J; Zhu Y; Deng J; Wang MW
    J Biomol Screen; 2015 Mar; 20(3):318-29. PubMed ID: 25520370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The contract research organization and the commercialization of scientific research.
    Mirowski P; Van Horn R
    Soc Stud Sci; 2005 Aug; 35(4):503-48. PubMed ID: 16304738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Past, present, and future industrial biotechnology in China.
    Li Z; Ji X; Kan S; Qiao H; Jiang M; Lu D; Wang J; Huang H; Jia H; Ouyuang P; Ying H
    Adv Biochem Eng Biotechnol; 2010; 122():1-42. PubMed ID: 20582527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biopharmaceutical innovation system and the influence of policies:the case of taiwan (2000-2008).
    Chung CC
    Int J Health Policy Manag; 2013 Aug; 1(2):125-30. PubMed ID: 24596851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catching up in pharmaceuticals: government policies and the rise of genomics.
    Benner M
    Aust Health Rev; 2004 Nov; 28(2):161-70. PubMed ID: 15527396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.